STAT+: For Swedish professor and his tiny biotech, Alzheimer’s drug means vindication and a fortune
Last month, word spread that a drug was finally shown to slow Alzheimer’s disease, and…
Category: Alzheimer’s
STAT+: Mutations tied to blood cancers and other diseases may surprisingly protect against Alzheimer’s
ATLANTA — When key mutations strike bone marrow stem cells, known as hematopoietic stem cells,…
STAT+: In the blood of marathoning mice, scientists find clues to how exercise benefits the brain
If you give a mouse a wheel, it will run, and run, and run: between…
STAT+: Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial
Cortexyme, pressing forward after its novel approach to Alzheimer’s disease failed in a mid-stage trial,…
STAT+: ‘Quite puzzling’ results in Alzheimer’s study cloud future of tau-targeting antibody treatment
New clinical trial results may temper early hope for an experimental Genentech treatment that targets…
STAT+: Alzheimer’s conference preview: Aduhelm debate persists, while field grapples with new targets and directions
When physicians and scientists involved in Alzheimer’s disease gather in Boston next week for an…
Mouse experiments with a decades-old drug suggest a new approach to Alzheimer’s treatment
A generic drug used widely to treat swelling associated with hypertension and heart failure showed…
STAT+: Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard
Biogen and its Japanese partner Eisai announced Monday evening the start of an application process…
STAT+: In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s
Cassava Sciences CEO Remi Barbier on Monday shifted his defense of the company’s embattled treatment…
STAT+: In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment
Eli Lilly said Thursday that it will seek a fast U.S. approval for its drug…
Newly disclosed FDA documents reveal agency’s unprecedented path to approving Aduhelm
Chastened after a decisively negative review from outside advisers, the Food and Drug Administration convened…
Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision
Harry Johns is ready to stop talking about whether or not the Food and Drug…
Third member of FDA expert committee resigns over controversial Alzheimer’s therapy decision
A third member of a Food and Drug Administration expert panel has resigned over the…
Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval
Following the Food and Drug Administration’s polarizing authorization of the Alzheimer’s therapy Aduhelm on Monday,…
Opinion: Bad medicine: aducanumab is a lackluster drug with a high price tag
Controversy has swirled around aducanumab, an experimental drug developed by Biogen, long before the FDA…
Opinion: If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it
Most visits to the memory center where I care for individuals living with Alzheimer’s disease…
Opinion: Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark
One morning in 2012, my wife Geri looked in the mirror and failed to recognize…
Side Effects of Statins and Dementia
Based on some early studies, the Food and Drug Administration (FDA) added a warning on…
STAT+: Eli Lilly releases detailed results on Alzheimer’s drug, as data divide researchers
Eli Lilly’s experimental Alzheimer’s medicine donanemab showed some of the best early results seen by…
STAT+: What to look for in Lilly’s eagerly awaited Alzheimer’s data
Earlier this year, amid the increasingly bruising debate over Biogen’s controversial treatment for Alzheimer’s disease,…
STAT+: How a scientific journal’s ‘grotesque overreaction’ inflamed the contentious debate over Biogen’s Alzheimer’s drug
A science journal owned by the Alzheimer’s Association punished a trio of leading researchers after…
STAT+: Eli Lilly says drug slowed Alzheimer’s decline in preliminary study
An experimental medicine appeared to slow the decline of patients with the early symptoms of…
.jpg)
The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review
The Food and Drug Administration has agreed to review a marketing application submitted by Biogen…
Turmeric Side Effects and Usage Challenges: How to Get the Full Benefits (Part 2)
The long list of turmeric supplement benefits is quite impressive and appealing (read more in…
Does Music Affect Memory? Music Therapy May Help Dementia Patients
Whenever I went to see my grandmother in her nursing home and my visit coincided…
17 CoQ10 Benefits You Can Enjoy Yourself
CoQ10, or coenzyme Q10, is a naturally produced enzyme found in the mitochondria in every…
.jpg)
Opinion: Hospitalized adults need their caregivers — they aren’t visitors
Social distancing, self-isolation, quarantine: These are among the essential public health interventions for the Covid-19…
STAT Plus: Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab
As U.S. regulators consider whether to approve the first new treatment for Alzheimer’s disease in…
STAT Plus: At JPM, a debate on Alzheimer’s disease, some family drama in oncology, and a beaten-down biotech
SAN FRANCISCO — While the early hours of biotech’s biggest annual meeting didn’t bring any…